HF
HCWB icon

HRT Financial’s HCW Biologics HCWB Stock Holding History

HRT Financial’s Portfolio HCWB Stock Details HCWB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$67K Sell
13,583
-30,816
-69% -$175K ﹤0.01% 3709
2026
Q1 		$95K Buy
+44,399
New +$230K ﹤0.01% 3361
2024
Q4 		– Sell
-194
Closed -$25K – 2720
2024
Q3 		$25K Sell
194
-84
-30% -$11.4K ﹤0.01% 2169
2024
Q2 		$43K Sell
278
-27
-9% -$7.98K ﹤0.01% 1852
2024
Q1 		$122K Buy
+305
New +$97.5K ﹤0.01% 1842

Other funds holding HCWB

Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
CCM
Connective Capital Management Palo Alto, California $142M AUM 51.29% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
GSWM
Golden State Wealth Management Santa Ana, California $1.1B AUM 27.5% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
CIAM
Caitong International Asset Management Hong Kong $729M AUM 1,176.98% 1-Year Est. Return

HRT Financial's HCWB Position: Q2 2026 in Review

HRT Financial reduced its HCW Biologics (HCWB) stake by 69% in Q2 2026, selling an estimated $175K and leaving 13,583 shares worth $67K. The position accounts for ﹤0.01% of the portfolio, ranked #3709.

HRT Financial first reported a position in HCWB in Q1 2024 and has held it in 5 quarters since. The position peaked at $122K in Q1 2024. 12 funds tracked by Wall St. Rank hold HCWB as of Q2 2026.

  • HRT Financial held 13,583 shares of HCW Biologics worth $67K as of Q2 2026.
  • HRT Financial sold 30,816 HCW Biologics shares in Q2 2026, an estimated $175K.
  • HCW Biologics made up ﹤0.01% of HRT Financial's portfolio in Q2 2026, its #3709 holding.
  • HRT Financial first reported a position in HCW Biologics in Q1 2024 and has held it in 5 quarters since.
  • HRT Financial's HCW Biologics position peaked at $122K in Q1 2024.
  • 12 funds tracked by Wall St. Rank held HCW Biologics as of Q2 2026.

Based on HRT Financial's 13F filing for Q2 2026, filed 14 Aug 2026.